Embry Holdings (1388) Fair Value & Analysis
Consumer Cyclical · HK · Market cap HK$127M
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 2 days ago
Fair value updated Aug 13, 2026, revised from HK$0.2023 to HK$0.1991 (−1.6%) since Aug 5, 2026. Share price −5.5% over the past month.
Below-average quality, and screening another 23% overvalued on our models.
What matters now
- Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (HK$0.1481 to HK$0.2970) leaves room in how you read the outcome.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$0.2600 – HK$1.43 · fair‑value band HK$0.1481 – HK$0.2970 · the HK$0.2600 price screens above the HK$0.1991 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Embry Holdings (1388) currently trades at HK$0.2600, while our model-based Fair Value estimate is HK$0.1991, implying the stock looks roughly 23.4% overvalued today. The Quality Score stands at 47/100 (below-average quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Embry Holdings generated revenue of HK$1.2B at a net margin of -21.6%. Revenue grew 8.5% year over year. It earns a return on equity of -15.5%. Net debt stands at HK$287M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.1481 (bear case) to HK$0.2970 (bull case); at HK$0.2600, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 47% below its 52-week high, currently below its 200-day average. For context, the median of 10 Consumer Cyclical peers we cover trades at 27% fair-value upside, at -23%, 1388 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 1388 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 26
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Embry Holdings Limited, an investment holding company, designs, research, develops, manufactures, trades in, and sells ladies lingerie, brassieres, panties, swimwear, sleepwear, and others in Chinese Mainland, Hong Kong, and internationally.
Full company description
Embry Holdings Limited, an investment holding company, designs, research, develops, manufactures, trades in, and sells ladies lingerie, brassieres, panties, swimwear, sleepwear, and others in Chinese Mainland, Hong Kong, and internationally. The company sells its lingerie products primarily under the EMBRY FORM, FANDECIE, COMFIT, E-BRA, IVU, IADORE, EMBRYKIDS, and LIZA CHENG brands. It also holds trademark and invests in properties. The company sells its products directly to customers through retail outlets comprising concessionary counters and retail stores, as well as through online channel. The company was founded in 1975 and is headquartered in Kwai Chung, Hong Kong.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Embry Holdings reported revenue of HK$1.2B in FY2025 versus HK$1.7B in FY2021, a compound −8.3%/yr. Reported net income was −HK$253M in FY2025.
1388 screens 23% overvalued. Compare with H & M Hennes & Mauritz AB →
Peer Group
Apparel Manufacturing · 213 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Apparel Manufacturing median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Apparel Manufacturing stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| H & M Hennes & Mauritz AB HMB | kr 174.25 | kr 165.47 | -5% |
| LPP SA LPP | 22,220 PLN | 17,754 PLN | -20% |
| Bosideng International Holdings 3998 | HK$4.65 | HK$5.92 | +27% |
| Youngor Fashion Co 600177 | ¥7.78 | ¥5.59 | -28% |
| Page Industries Limited PAGEIND | ₹38,295 | ₹12,395 | -68% |
| Hla Group 600398 | ¥6.07 | ¥9.92 | +63% |
| Youngone Corporation 111770 | 85,200 KRW | 188,736 KRW | +122% |
| F&F Co 383220 | 68,800 KRW | 179,500 KRW | +161% |
| Youngone Holdings 009970 | 188,300 KRW | 697,038 KRW | +270% |
| Wiselink Co 8932 | 105.00 TWD | 37.95 TWD | -64% |
Compare Embry Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Cyclical stocks →
Frequently asked questions
Is Embry Holdings (1388) overvalued or undervalued?
What is the fair value of 1388?
What is the quality score of 1388?
What is the revenue of Embry Holdings (1388)?
What is the net profit margin of 1388?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Embry Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.